Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX

Authors: Spencer, Andrew, Moreau, Philippe, Mateos, Maria-Victoria, Goldschmidt, Hartmut, Suzuki, Kenshi, Levin, Mark-David, Sonneveld, Pieter, Orlowski, Robert Z., Yoon, Sung-Soo, Usmani, Saad Z., Weisel, Katja, Reece, Donna, Ahmadi, Tahamtan, Pei, Huiling, Mayo, Wendy Garvin, Gai, Xue, Carey, Jodi, Bartlett, J. Blake, Carson, Robin, Dimopoulos, Meletios A.

Source: In Blood Advances 23 January 2024 8(2):388-398

Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial

Authors: Hillmen, Peter, Robak, Tadeusz, Janssens, Ann, Babu, K Govind, Kloczko, Janusz, Grosicki, Sebastian, Doubek, Michael, Panagiotidis, Panagiotis, Kimby, Eva, Schuh, Anna, Pettitt, Andrew R, Boyd, Thomas, Montillo, Marco, Gupta, Ira V, Wright, Oliver, Dixon, Iestyn, Carey, Jodi L, Chang, Chai-Ni, Lisby, Steen, McKeown, Astrid, Offner, Fritz

Source: In The Lancet 9-15 May 2015 385(9980):1873-1883

Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial.

Authors: Dimopoulos, Meletios A.¹ (AUTHOR) mdimop@med.uoa.gr, Oriol, Albert² (AUTHOR), Nahi, Hareth³ (AUTHOR), San-Miguel, Jesus⁴ (AUTHOR), Bahlis, Nizar J.⁵ (AUTHOR), Usmani, Saad Z.⁶ (AUTHOR), Rabin, Neil⁷ (AUTHOR), Orlowski, Robert Z.⁸ (AUTHOR), Suzuki, Kenshi⁹ (AUTHOR), Plesner, Torben¹⁰ (AUTHOR), Yoon, Sung-Soo¹¹ (AUTHOR), Ben Yehuda, Dina¹² (AUTHOR), Richardson, Paul G.¹³ (AUTHOR), Goldschmidt, Hartmut¹⁴ (AUTHOR), Reece, Donna¹⁵ (AUTHOR), Ahmadi, Tahamtan¹⁶ (AUTHOR), Qin, Xiang¹⁷ (AUTHOR), Garvin Mayo, Wendy¹⁸ (NURSE), Gai, Xue¹⁹ (AUTHOR), Carey, Jodi¹⁷ (AUTHOR)

Source: Journal of Clinical Oncology. 3/10/2023, Vol. 41 Issue 8, p1590-1599. 10p.

Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial.

Authors: Sonneveld, Pieter¹ (AUTHOR) p.sonneveld@erasmusmc.nl, Chanan-Khan, Asher² (AUTHOR), Weisel, Katja³ (AUTHOR), Nooka, Ajay K.⁴ (AUTHOR), Masszi, Tamas⁵ (AUTHOR), Beksac, Meral⁶ (AUTHOR), Spicka, Ivan⁷ (AUTHOR), Hungria, Vania⁸ (AUTHOR), Munder, Markus⁹ (AUTHOR), Mateos, Maria-Victoria¹⁰ (AUTHOR), Mark, Tomer M.¹¹ (AUTHOR), Levin, Mark-David¹² (AUTHOR), Ahmadi, Tahamtan¹³ (AUTHOR), Qin, Xiang¹⁴ (AUTHOR), Garvin Mayo, Wendy¹⁵ (NURSE), Gai, Xue¹⁶ (AUTHOR), Carey, Jodi¹⁴ (AUTHOR), Carson, Robin¹⁴ (AUTHOR), Spencer, Andrew¹⁷ (AUTHOR)

Source: Journal of Clinical Oncology. 3/10/2023, Vol. 41 Issue 8, p1600-1609. 10p.

P-260: Daratumumab (DARA) plus bortezomib and dexamethasone (D-Vd) or lenalidomide and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): subgroup analyses of CASTOR and POLLUX

Authors: Mateos, María-Victoria, Richardson, Paul, Weisel, Katja, Moreau, Philippe, San-Miguel, Jesus, Goldschmidt, Hartmut, Orlowski, Robert, Sonneveld, Pieter, Reece, Donna E., Suzuki, Kenshi, Bahlis, Nizar, Yoon, Sung-Soo, Spencer, Andrew, Nooka, Ajay, Hungria, Vania, Plesner, Torben, Yehuda, Dina Ben, Pei, Huiling, Mayo, Wendy Garvin, Gai, Xue, Carey, Jodi, Carson, Robin, Dimopoulos, Meletios A.

Source: In Clinical Lymphoma, Myeloma and Leukemia August 2022 22 Supplement:S179-S180

Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B‐cell lymphoma in the phase III clinical trial of R‐CHOP ± ibrutinib.

Authors: Balasubramanian, Sriram, Wang, Songbai, Major, Christopher, Hodkinson, Brendan, Schaffer, Michael, Sehn, Laurie H., Johnson, Peter, Zinzani, Pier Luigi, Carey, Jodi, Shreeve, S. Martin, Sun, Steven, Gerecitano, John, Vermeulen, Jessica, Staudt, Louis M., Wilson, Wyndham

Source: British Journal of Haematology; Jul2021, Vol. 194 Issue 1, p83-91, 9p

Subject Terms: DIFFUSE large B-cell lymphomas, GENE expression profiling, ANTINEOPLASTIC combined chemotherapy protocols, SURVIVAL rate, CLINICAL trials

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911)

Authors: Hillmen, Peter, Robak, Tadeusz, Janssens, Ann ^*, Govindbabu, K ^*, Grosicki, Sebastian, Mayer, Jiri, Panagiotidis, Panagiotis, Kimby, Eva, Schuh, Anna ^*, Boyd, Thomas ^*, Montillo, Marco, McKeown, Astrid ^*, Carey, Jodi L ^*, Gupta, Ira V ^*, Chang, Chai-Ni ^*, Lisby, Steen, Offner, Fritz

Source: In Blood 15 November 2013 122(21):528-528

This result is not displayed to guests.
Login for full access.